share_log

Wedbush Maintains Outperform on Elevation Oncology, Raises Price Target to $6

Benzinga ·  Jun 5, 2023 08:17

Wedbush analyst Robert Driscoll maintains Elevation Oncology (NASDAQ:ELEV) with a Outperform and raises the price target from $4 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment